Literature DB >> 1300350

Efficacy of praziquantel treatment of schistosomiasis in a non-endemic country: a follow-up of parasitological, clinical and immunological parameters.

M Giboda1, J Loudová, O Shonová, E Boucková, J Horácek, P Numrich, A Ruppel, J Vítovec, S Lukes, P Noll.   

Abstract

Schistosomiasis patients were immigrants to Czechoslovakia from Angola and Yemen. Most of them had light or moderate infections and felt subjectively healthy. They received treatment with praziquantel (two doses with a total of 40 mg/kg) and were followed up for several years. In nine of 13 patients, Schistosoma haematobium or S. mansoni eggs with undamaged miracidia were detected in biopsies from the bladder or the rectum one year or later after treatment. Granulomatous reactions in the rectum and bladder lesions of stage 1 including thickened bladder walls persisted in most of the patients. Antibody levels against adult S. mansoni worm antigen remained elevated for at least two years after therapy in some patients and declined in others. Among the nine patients, for whom pre- and post-treatment sera were available, the changes in relative levels of antibodies did not strictly correlate with the continued presence of schistosome eggs in, or their absence from, biopsies. We discuss the results obtained with sensitive diagnostic techniques in the absence of subjectively perceived disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1300350

Source DB:  PubMed          Journal:  J Hyg Epidemiol Microbiol Immunol        ISSN: 0022-1732


  3 in total

Review 1.  Schistosomiasis at the Crossroad to Elimination: Review of Eclipsed Research with Emphasis on the Post-Transmission Agenda.

Authors:  Michal Giboda; Robert Bergquist; Jürg Utzinger
Journal:  Trop Med Infect Dis       Date:  2022-03-31

2.  Effect of school based treatment on the prevalence of schistosomiasis in endemic area in yemen.

Authors:  A Abdulrab; A Salem; F Algobati; S Saleh; K Shibani; R Albuthigi
Journal:  Iran J Parasitol       Date:  2013-04       Impact factor: 1.012

3.  Praziquantel, mefloquine-praziquantel, and mefloquine-artesunate-praziquantel against Schistosoma haematobium: a randomized, exploratory, open-label trial.

Authors:  Jennifer Keiser; Kigbafori D Silué; Lukas K Adiossan; Nicaise A N'Guessan; N'Chou Monsan; Jürg Utzinger; Eliézer K N'Goran
Journal:  PLoS Negl Trop Dis       Date:  2014-07-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.